Editorial

March 31, 2024


JUO, the Journal of Urologic Oncology, Celebrates Its Second Anniversary
Cheol Kwak
J Urol Oncol. 2024;22(1):1-3.

Invited Review

March 31, 2024


Prostate-Specific Antigen-Based Prostate Cancer Screening: One for All or Individualized for Each Race? – A Narrative Review
Chang Wook Jeong
J Urol Oncol. 2024;22(1):4-10.

Invited Review

March 31, 2024


Multidisciplinary Team Approach in Prostate-Specific Membrane Antigen Theranostics for Prostate Cancer: A Narrative Review
Minseok Suh, Gi Jeong Cheon
J Urol Oncol. 2024;22(1):11-20.

Original Article

March 31, 2024


High-Grade Late Urinary Toxicity Following Salvage Radiotherapy After Radical Prostatectomy: A Retrospective Cohort Study
Seung-Kwon Choi, Myong Kim, Sang Mi Lee, et al.
J Urol Oncol. 2024;22(1):21-28.

Original Article

March 31, 2024


Enzalutamide Maintenance Following Docetaxel in Metastatic Castration-Naive Prostate Cancer: A Pilot Feasibility Study
Sung Hee Lim, Sung Wook Cho, Jae Hoon Chung, et al.
J Urol Oncol. 2024;22(1):29-33.

Systemic Review and Meta-analysis

March 31, 2024


Targeted Therapy Following Metastasectomy for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-analysis
Hui Mo Gu, Seung Il Jung, Dongdeuk Kwon, et al.
J Urol Oncol. 2024;22(1):34-41.

Original Article

March 31, 2024


Global Renal Cell Carcinoma Research Trends Over 30 Years: A PRISMA-Compliant Bibliometric Analysis
Jung Hoon Kim, Ji Woong Hwang
J Urol Oncol. 2024;22(1):42-51.

Original Article

March 31, 2024


Prognostic Factors and Cancer-Specific Survival of Surgically Managed Renal Cell Carcinoma With Venous Thrombus: A 30-Year Experience at a Tertiary Referral Center
Hyun Young Lee, Yunjoong Kim, Bumjin Lim, et al.
J Urol Oncol. 2024;22(1):52-58.

Original Article

March 31, 2024


Clinical Characteristics and Outcomes of TFE3-Rearranged/TFEB-Altered Renal Cell Carcinoma with Systemic Therapies, Including Tyrosine Kinase Inhibitors or Immune Checkpoint Inhibitors: An Observational Study
Joohyun Hong, Ghee Young Kwon, Minyong Kang, et al.
J Urol Oncol. 2024;22(1):59-67.

Invited Review

March 31, 2024


Nephron-Sparing Surgery for Upper Urinary Tract Urothelial Carcinoma
Sung Han Kim, Ilma S. Savul, Seth P. Lerner
J Urol Oncol. 2024;22(1):68-77.

Systemic Review and Meta-analysis

March 31, 2024


Poorer Outcomes in Bladder Cancer Patients With Diabetes: A Systematic Review and Meta-analysis Addressing Over 226,472 Bladder Cancer Patients
Stefani Frost, Parisa Ziarati, Ryan Moen, et al.
J Urol Oncol. 2024;22(1):78-94.

Erratum

March 31, 2024


Declaration of Conflict of Interest for Editorial Board Members’ Articles
J Urol Oncol. 2024;22(1):95-96.
Epidemiology of Urologic Cancer in Korea: Nationwide Trends in the Last 2 Decades
Sang Heon Han, Hyeong Dong Yuk
J Urol Oncol. 2023;21(1):32-44.

Original Article

Mar 31, 2023

The Landscape of Epidemiology in Urologic Cancers
An Update of Prostate-Specific Membrane Antigen Theranostics in Prostate Cancer
Jeong Hee Hong
Korean J Urol Oncol. 2022;20(4):207-222.

Review Article

Nov 30, 2022

Complex Epidemiology of Prostate Cancer in Asian Countries
Kagenori Ito, Takahiro Kimura
J Urol Oncol. 2023;21(1):5-13.

Review Article

Mar 31, 2023

The Evolving Role of Checkpoint Inhibitors in the Treatment of Urothelial Carcinoma: A Literature Review of Practice-Changing Trials
Sang Hun Song, Jong Jin Oh
J Urol Oncol. 2023;21(2):154-164.

Invited Review

Jul 31, 2023

Trimodality Therapy and Immuno-Oncology for Bladder Cancer
Prostate Imaging and Reporting and Data System Version 2.1: Limitations for Clinical Use
Byung Kwan Park
J Urol Oncol. 2023;21(2):106-111.

Invited Review

Jul 31, 2023

mpMRI in the Management of Prostate Cancer: Role, Limitation, and Cost-Effectiveness
Influence of Body Composition on the Perioperative and Survival Outcomes of Renal Cell Carcinoma
Edouard H. Nicaise, Benjamin N. Schmeusser, Yash B. Shah, et al.
J Urol Oncol. 2023;21(3):183-199.

Invited Review

Nov 30, 2023

Perioperative Considerations and Treatment for Advanced Renal Cell Carcinoma
The Important Role of Poly ADP-Ribose Polymerase Inhibitor in Prostate Cancer
Jae Young Joung, Sung Han Kim
Korean J Urol Oncol. 2022;20(1):1-11.

Review Article

Feb 24, 2022

The Incidence of Prostate-Specific Antigen Test in a Country With a Limited Social Perception of Prostate Cancer 2006-2016: Disparities Manifested by Residential Area
Young Hwii Ko, Byung Hoon Kim
Korean J Urol Oncol. 2022;20(1):43-51.

Original Article

Feb 24, 2022

2021 Consensus Statements on the Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma From the Korean Renal Cancer Study Group (KRoCS)
Chan Ho Lee, Minyong Kang, Cheol Kwak, et al.
Korean J Urol Oncol. 2022;20(3):151-162.

Review Article

Aug 25, 2022

Current Trends in Liquid Biopsy Technology for Early Diagnosis of Metastatic Renal Cell Carcinoma
Jeong Yoon Suh, Se Jung Maeng, Mirinae Kim, et al.
Korean J Urol Oncol. 2022;20(4):223-234.

Review Article

Nov 30, 2022

A Survey on the Quality of Life of Prostate Cancer Patients in Korean Prostate Cancer Patients Association
Yun-Sok Ha, Kwang Taek Kim, Wook Nam, et al.
Korean J Urol Oncol. 2022;20(4):265-272.

Original Article

Nov 30, 2022

The Current State and Future of Plasma Cell-Free DNA Analysis in Urologic Malignancies
Shusuke Akamatsu, Kei Mizuno, Takayuki Sumiyoshi, et al.
J Urol Oncol. 2023;21(1):23-31.

Review Article

Mar 31, 2023

Bladder Cancer in South Korea: Analysis of Trends and Risk Factors of Bladder Cancer in South Korea Using a Nationwide Database
Sangjun Yoo, Kyung-Do Han, Kwang Taek Kim, et al.
J Urol Oncol. 2023;21(1):45-52.

Original Article

Mar 31, 2023

Contemporary Management of Small Renal Masses by Urologic Oncologists: A 2022 Korean Renal Cancer Study Group Practice Pattern Survey
Joongwon Choi, Cheryn Song, Jungyo Suh, et al.
J Urol Oncol. 2023;21(1):59-69.

Original Article

Mar 31, 2023

Bladder Preservation With Transurethral Tumor Resection and Intravesical BCG Instillation in Superficial Muscle-Invasive Bladder Cancer: A 10-Year Follow-up
Dong Gyun Kim, Ji Eun Heo, Kang Su Cho, et al.
J Urol Oncol. 2023;21(1):70-78.

Original Article

Mar 31, 2023

A Cost-Benefit Comparison of Biparametric Magnetic Resonance Imaging Versus Conventional Prostate Cancer Screening
Jung Sik Huh, Kyung Kgi Park
J Urol Oncol. 2023;21(2):121-127.

Original Article

Jul 31, 2023

mpMRI in the Management of Prostate Cancer: Role, Limitation, and Cost-Effectiveness
Korean Urologic Oncology Society Guidelines: Does Angioembolization Improve the Quality of Life for Renal Cell Carcinoma Patients With Intractable Symptoms Who Are Unfit for Surgery?
Ja Yoon Ku, Hui Mo Gu, Seong Hyeon Yu, et al.
J Urol Oncol. 2023;21(2):140-147.

Invited Review

Jul 31, 2023

Genetic Testing and Nonsurgical Management for Renal Cell Carcinoma
The Role of Magnetic Resonance Imaging (MRI) and MRI-Targeted Biopsy for Active Surveillance
Chang Wook Jeong
J Urol Oncol. 2023;21(2):97-105.

Invited Review

Jul 31, 2023

mpMRI in the Management of Prostate Cancer: Role, Limitation, and Cost-Effectiveness
Efficacy of Partial Nephrectomy in the Management of Unpredicted pT3a Renal Cell Carcinoma
Dongsu Kim, Bumjin Lim, Jungyo Suh, et al.
J Urol Oncol. 2023;21(2):148-153.

Original Article

Jul 31, 2023

Genetic Testing and Nonsurgical Management for Renal Cell Carcinoma
The Predictive Value of the Preoperative Systemic Inflammatory Response Indices in Non–Organ-Confined Disease in Upper Urinary Tract Urothelial Carcinoma
Sung Kyung Choi, Chan Hoon Gwak, Jungyo Suh, et al.
J Urol Oncol. 2023;21(2):174-180.

Original Article

Jul 31, 2023

Trimodality Therapy and Immuno-Oncology for Bladder Cancer
Impact of Multiparametric Magnetic Resonance Imaging for the Prediction of Extraprostatic Extension According to the National Comprehensive Cancer Network Risk Stratification in Prostate Cancer
Jae Hoon Kang, Jun-Koo Kang, Jae-Wook Chung, et al.
J Urol Oncol. 2023;21(2):112-120.

Topic Article

Jul 31, 2023

mpMRI in the Management of Prostate Cancer: Role, Limitation, and Cost-Effectiveness
Radical Cystectomy Versus Bladder-Preserving Therapy in Muscle-Invasive Bladder Cancer Patients After Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Multicenter Retrospective Analysis
Youngheun Jo, Jun Seok Kim, Yoo Sub Shin, et al.
J Urol Oncol. 2023;21(2):165-173.

Original Article

Jul 31, 2023

Trimodality Therapy and Immuno-Oncology for Bladder Cancer
Genetic Testing for Prostate Cancer, Urothelial Cancer, and Kidney Cancer
Hyunho Han, Minyong Kang, Seok-Soo Byun, et al.
J Urol Oncol. 2023;21(2):128-139.

Invited Review

Jul 31, 2023

Genetic Testing and Nonsurgical Management for Renal Cell Carcinoma
Preoperative Renal Artery Embolization Before Radical Nephrectomy for Nonmetastatic Renal Cell Carcinoma: A Propensity Score Matched Analysis
Jin Noh, Sang Hun Song, Gyoohwan Jung, et al.
J Urol Oncol. 2023;21(3):200-207.

Topic Article

Nov 30, 2023

Perioperative Considerations and Treatment for Advanced Renal Cell Carcinoma
The Future of Adjuvant Therapy in Renal Cell Carcinoma: Recent Insights and Prospects
Hyerim Ha, Joo Han Lim
J Urol Oncol. 2023;21(3):208-216.

Invited Review

Nov 30, 2023

Perioperative Considerations and Treatment for Advanced Renal Cell Carcinoma
Role of Radiotherapy in Metastatic Renal Cell Carcinomas: An Evolutionary Journey in a Misunderstood Histological Type
Chan Woo Wee, Jaeho Cho
J Urol Oncol. 2023;21(3):217-227.

Invited Review

Nov 30, 2023

Perioperative Considerations and Treatment for Advanced Renal Cell Carcinoma
Optimal Management of Bacillus Calmette-Guérin–Refractory Non–Muscle-Invasive Bladder Cancer in 2023
Jiwoong Yu, Hyun Hwan Sung
J Urol Oncol. 2023;21(3):228-240.

Invited Review

Nov 30, 2023

Optimal Management for BCG Unresponsive Non-Muscle-Invasive Bladder Cancer
Clinical Outcomes of Patients With Variant Histology of Urothelial Carcinoma After Radical Cystectomy
Dan Bee Lee, Jae Yeon Kim, Yun Ha Lee, et al.
J Urol Oncol. 2023;21(3):249-256.

Original Article

Nov 30, 2023

Optimal Management for BCG Unresponsive Non-Muscle-Invasive Bladder Cancer
Predictive Factors of Abiraterone Response in Patients With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
Jaeyoung Cho, Jungyo Suh, Dalsan You, et al.
J Urol Oncol. 2023;21(3):257-263.

Topic Article

Nov 30, 2023

Clinical Predictors of ARTA Response in Metastatic Prostate Cancer
Nonregional Lymph Node Metastasis as a Predictor of Early Progression When Using Androgen Receptor Targeting Agents in Patients With Metastatic Castration-Resistant Prostate Cancer Without Previous Chemotherapy
Sihyeon Kim, Beom Yong Rho, Dong Hyuk Kang, et al.
J Urol Oncol. 2023;21(3):264-270.

Topic Article

Nov 30, 2023

Clinical Predictors of ARTA Response in Metastatic Prostate Cancer

Journal of
Urologic Oncology

Print ISSN: 2951-603X
Online ISSN: 2982-7043


Editorial Office
Department of Urology, Seoul National University Hospital, Seoul National University College of Medicine,
101 Daehak-ro, Jongno-gu, Seoul 03080, Korea
TEL: +82-2-2072-0817,   FAX: +82-2-742-4665   Email: journal@e-juo.org
Korean Urological Oncology Society
50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea
Tel: +82-2-704-8574, E-mail: kspe.editor@gmail.com

Copyright © The Korean Urological Oncology Society.

Developed in M2PI